These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 33763335)

  • 1. Phosphodiesterase-4 Inhibition in Psoriasis.
    Milakovic M; Gooderham MJ
    Psoriasis (Auckl); 2021; 11():21-29. PubMed ID: 33763335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase-4 Inhibition in the Management of Psoriasis.
    Crowley EL; Gooderham MJ
    Pharmaceutics; 2023 Dec; 16(1):. PubMed ID: 38258034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
    Gooderham M; Papp K
    BioDrugs; 2015 Oct; 29(5):327-39. PubMed ID: 26481941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
    Bianchi L; Del Duca E; Romanelli M; Saraceno R; Chimenti S; Chiricozzi A
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases.
    Li H; Zuo J; Tang W
    Front Pharmacol; 2018; 9():1048. PubMed ID: 30386231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.
    Bhat A; Ray B; Mahalakshmi AM; Tuladhar S; Nandakumar DN; Srinivasan M; Essa MM; Chidambaram SB; Guillemin GJ; Sakharkar MK
    Pharmacol Res; 2020 Oct; 160():105078. PubMed ID: 32673703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives.
    Sakkas LI; Mavropoulos A; Bogdanos DP
    Curr Med Chem; 2017; 24(28):3054-3067. PubMed ID: 28554321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.
    Jarnagin K; Chanda S; Coronado D; Ciaravino V; Zane LT; Guttman-Yassky E; Lebwohl MG
    J Drugs Dermatol; 2016 Apr; 15(4):390-6. PubMed ID: 27050693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.
    Dalamaga M; Karampela I; Mantzoros CS
    Metabolism; 2020 Aug; 109():154282. PubMed ID: 32497535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ZORYVE
    Gupta AK; Ravi SP; Vincent K; Abramovits W
    Skinmed; 2023; 21(5):357-359. PubMed ID: 37945365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.
    Wittmann M; Helliwell PS
    Dermatol Ther (Heidelb); 2013 Jun; 3(1):1-15. PubMed ID: 23888251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase 4 inhibitors.
    Zebda R; Paller AS
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S43-S52. PubMed ID: 29248522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
    Pincelli C; Schafer PH; French LE; Augustin M; Krueger JG
    J Drugs Dermatol; 2018 Aug; 17(8):835-840. PubMed ID: 30124722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between in vitro cyclic adenosine monophosphate phosphodiesterase inhibition and in vivo anti-inflammatory effect.
    Goyarts E; Mammone T; Muizzuddin N; Marenus K; Maes D
    Skin Pharmacol Appl Skin Physiol; 2000; 13(2):86-92. PubMed ID: 10754456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
    Schafer P
    Biochem Pharmacol; 2012 Jun; 83(12):1583-90. PubMed ID: 22257911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apremilast for the treatment of psoriasis.
    Chimenti MS; Gramiccia T; Saraceno R; Bianchi L; Garofalo V; Buonomo O; Perricone R; Chimenti S; Chiricozzi A
    Expert Opin Pharmacother; 2015; 16(13):2083-94. PubMed ID: 26243735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. East Indian Sandalwood Oil Is a Phosphodiesterase Inhibitor: A New Therapeutic Option in the Treatment of Inflammatory Skin Disease.
    Sharma M; Levenson C; Browning JC; Becker EM; Clements I; Castella P; Cox ME
    Front Pharmacol; 2018; 9():200. PubMed ID: 29593534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis.
    Bäumer W; Hoppmann J; Rundfeldt C; Kietzmann M
    Inflamm Allergy Drug Targets; 2007 Mar; 6(1):17-26. PubMed ID: 17352685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.
    Moustafa F; Feldman SR
    Dermatol Online J; 2014 May; 20(5):22608. PubMed ID: 24852768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of psoriasis with crisaborole.
    Lee EB; Lebwohl MG; Wu JJ
    J Dermatolog Treat; 2019 Mar; 30(2):156-157. PubMed ID: 29812961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.